Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 6 (PDF)

Found: NA NA NA NA NA NA NA NA NA NA NA NA Peripheral vascular disease18,043 0.90 17,8640.90 0.001 33 0.70

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 2 (PDF)

Found: We did not identify any signals for narcolepsy, cerebral venous sinus thrombosis, Kawasaki disease,

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 4 (PDF)

Found: 2) causes coronavirus disease 2019 (COVID -19) and has led to a global pandemic (1), and a mass

---

Written Question

Cardiovascular Diseases

Tuesday 27th February 2024

Asked by: Jim Shannon (Democratic Unionist Party - Strangford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data her Department holds on the number of cases of (a) vascular and (b) venous disease.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

Cardiovascular disease affects approximately seven million people in the United Kingdom, and is a significant cause of disability and death. Further information is available at the following link:

https://www.england.nhs.uk/ourwork/clinical-policy/cvd/

---

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 17 October 2022
Document: Freedom of Information request (FOI 22/1012) - attachment (PDF)

Found: More recently, vascular disease, age 2: 65 years and female sex have been included in the modified CHA2DS2

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 24 October 2022
Document: Freedom of Information request (FOI 22/990 and FOI 22/901) - attachment (PDF)

Found: Important co -morbidities The most common co -morbidities include CHF, peripheral vascular disease,

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 17 October 2022
Document: Freedom of Information request (FOI 22/981) - attachment 10 (PDF)

Found: hypomotility disorders NEC Constipation 3 0 Gastrooesophageal reflux disease 4 0

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 17 October 2022
Document: Freedom of Information request (FOI 22/981) - attachment 3 (PDF)

Found: vascular disorders (excl retinopathy) Retinal aneurysm 1 0 Retinal, choroid and vitreous infections

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 17 October 2022
Document: Freedom of Information request (FOI 22/981) - attachment 8 (PDF)

Found: corneal bleeding and vascular disorders Conjunctival haemorrhage 1 0 Eyelid movement disorders

---